CoChat

Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study

Open access

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Abstract

Background. Nonalcoholic fatty liver disease (NAFLD) is commonly observed in patients with type 2 diabetes (T2D). Semaglutide, a glucagon-like peptide 1 receptor agonist, may have a therapeutic role by targeting common mechanisms involved in the pathophysiology of T2D and NAFLD. The study aimed to assess the effectiveness of Semaglutide on NAFLD in patients with T2D. Methods. Forty-eight patients were treated with subcutaneous Semaglutide in add-on to metformin for 52 weeks. After the baseline visit (T0), follow-up was scheduled quarterly (T3, and T6) and then at 12 months of therapy (T12). During each visit, body composition was analyzed by phase-sensitive bio-impedance, and NAFLD was diagnosed and staged by Ultrasound (US) imaging. Surrogate biomarkers of NAFLD were also calculated and followed over time. Results. A significant decrease in anthropometric and glucometabolic parameters, insulin resistance, liver enzymes, and laboratory indices of hepatic steatosis was observed during treatment. Similarly, fat mass and visceral adipose tissue (VAT) decreased over time more than skeletal muscle and free-fat mass. US-assessed VAT thickness and the 12-point steatosis score also declined at T3 up to T12. Liver steatosis improved in most patients (70%), showing a reduction by at least one class in the semiquantitative US staging. Conclusion. Besides glucose control and body composition improvements, Semaglutide was effective in ameliorating the clinical appearance and severity of NAFLD in T2D patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/nu14214673

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Ultrasound grading of hepatic steatosis: (A) Normal Liver (score 0); (B) Mild Steatosis (score 1–4); (C) Moderate Steatosis (score 5–8); (D) Severe Steatosis (score 9–12).
Figure 1 Ultrasound grading of hepatic steatosis: (A) Normal Liver (score 0); (B) Mild Steatosis (score 1–4); (C) Moderate Steatosis (score 5–8); (D) Severe Steatosis (score 9–12).CC BY · PubMed Central
Figure 2 Baseline distribution of BMI classes of the study population: normal weight (BMI < 25 kg/m2); overweight (25 < BMI < 30 kg/m2); mild obesity (30 < BMI < 35 kg/m2); moderate-to-severe obesity (BMI ≥ 35 kg/m2).
Figure 2 Baseline distribution of BMI classes of the study population: normal weight (BMI < 25 kg/m2); overweight (25 < BMI < 30 kg/m2); mild obesity (30 < BMI < 35 kg/m2); moderate-to-severe obesity (BMI ≥ 35 kg/m2).CC BY · PubMed Central
Figure 3 Baseline distribution of NAFLD severity according to a semiquantitative US-score in the study population. Abbreviation: NAFLD = non-alcoholic fatty liver disease; US = ultrasonographic.
Figure 3 Baseline distribution of NAFLD severity according to a semiquantitative US-score in the study population. Abbreviation: NAFLD = non-alcoholic fatty liver disease; US = ultrasonographic.CC BY · PubMed Central
Figure 4 Values are expressed as a percentage of changes in anthropometric (Body Weight, BMI, Waist Circumference), and glucometabolic (Fasting Glycemia, Glycated Hemoglobin, Fasting Serum Insulin, and HOMA-IR index) parameters compared to the baseline (T0 = 100%). Changes versus T0: ** p < 0.01. Changes versus former time: # p < 0.05; ## p < 0.01. Abbreviations: BMI = Body Mass Index; HOMA-IR = homeostasis model assessment of insulin resistance.
Figure 4 Values are expressed as a percentage of changes in anthropometric (Body Weight, BMI, Waist Circumference), and glucometabolic (Fasting Glycemia, Glycated Hemoglobin, Fasting Serum Insulin, and HOMA-IR index) parameters compared to the baseline (T0 = 100%). Changes versus T0: ** p < 0.01. Changes versus former time: # p < 0.05; ## p < 0.01. Abbreviations: BMI = Body Mass Index; HOMA-IR = homeostasis model assessment of insulin resistance.CC BY · PubMed Central
Figure 5 Mean changes in serum values of Total Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein (HDL) Cholesterol, and Triglycerides (mg/dL) through the study period. Means are reported as Least Squared Means estimated by Mixed Model analysis. Variation versus T0: * p < 0.05; ** p < 0.01. Variation versus previous time: ## p < 0.01.
Figure 5 Mean changes in serum values of Total Cholesterol, Low-Density Lipoprotein (LDL) Cholesterol, High-Density Lipoprotein (HDL) Cholesterol, and Triglycerides (mg/dL) through the study period. Means are reported as Least Squared Means estimated by Mixed Model analysis. Variation versus T0: * p < 0.05; ** p < 0.01. Variation versus previous time: ## p < 0.01.CC BY · PubMed Central
Figure 6 Mean changes, expressed as percentage changes from T0, in clinical parameters, eGFR, and serum C-peptide over the follow-up (T0, T3, T6, T12). No statistically significant changes have been found. Abbreviation: Glomerular filtration rate (eGFR).
Figure 6 Mean changes, expressed as percentage changes from T0, in clinical parameters, eGFR, and serum C-peptide over the follow-up (T0, T3, T6, T12). No statistically significant changes have been found. Abbreviation: Glomerular filtration rate (eGFR).CC BY · PubMed Central
Figure 7 Mean changes in serum values of AST, ALT, and γGT (U/L) over the study period. Means are reported as least squared means estimated by mixed model analysis. Variation versus T0: * p < 0.05; ** p < 0.01. Abbreviations AST: ASpartate aminoTransferase; ALT: ALanine aminoTransferase; γGT: gamma-glutamyl transferase.
Figure 7 Mean changes in serum values of AST, ALT, and γGT (U/L) over the study period. Means are reported as least squared means estimated by mixed model analysis. Variation versus T0: * p < 0.05; ** p < 0.01. Abbreviations AST: ASpartate aminoTransferase; ALT: ALanine aminoTransferase; γGT: gamma-glutamyl transferase.CC BY · PubMed Central
Figure 8 Mean changes, expressed as percentage changes from T0, in biometrical indices of hepatic fibrosis (APRI) and steatosis (HSI, FLI), and US parameters (US-SAT, VAT, and LSS) over the follow-up (T0, T3, T6, T12). Variation versus T0: * p < 0.05; ** p < 0.01. Variation versus previous time: # p < 0.05; ## p < 0.01. Abbreviations: APRI: Aspartate aminotransferase to Platelet Ratio Index; HSI: Hepatic Steatosis Index; FLI: Fatty Liver Index; US: ultrasound; SAT: Subcutaneous Adipose Tissue; VAT: Visceral Adipose Tissue; LSS: Liver Steatosis Score.
Figure 8 Mean changes, expressed as percentage changes from T0, in biometrical indices of hepatic fibrosis (APRI) and steatosis (HSI, FLI), and US parameters (US-SAT, VAT, and LSS) over the follow-up (T0, T3, T6, T12). Variation versus T0: * p < 0.05; ** p < 0.01. Variation versus previous time: # p < 0.05; ## p < 0.01. Abbreviations: APRI: Aspartate aminotransferase to Platelet Ratio Index; HSI: Hepatic Steatosis Index; FLI: Fatty Liver Index; US: ultrasound; SAT: Subcutaneous Adipose Tissue; VAT: Visceral Adipose Tissue; LSS: Liver Steatosis Score.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Cited by

See all 85

Metadata

Authors
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., Triggiani, V., De Pergola, G., & Piazzolla, G.
Affiliations
  • University of Bari Aldo Moro (IT)
  • Gastroenterology Hospital "Saverio de Bellis" (IT)
  • National Institute of Gastroenterology IRCCS “S. de Bellis”, Research Hospital, Castellana Grotte, Via Turi 27, 70013 Bari, Italy
Corresponding author
Piazzolla, Giuseppina
Venue
Nutrients
Publisher
MDPI AG
Published
2022-11-04
Volume
14
Issue
21
Pages
4673
ISSN
2072-6643 (ISSN-L)
OpenAlex
W4308720508
Cited by
84
References
46
Citations by year
2026: 16 · 2025: 23 · 2024: 27 · 2023: 18
FWCI
12.27
Type
journal article
Language
en
Open access
Locations
  • Nutrients (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
semaglutide, non-alcoholic fatty liver disease, type 2 diabetes, GLP-1 receptor agonists, hepatic steatosis, visceral adipose tissue, body composition, insulin resistance, metformin add-on therapy, real-world effectiveness
MeSH terms
Semaglutide, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Humans, Prospective Studies, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. https://app.cochat.ai/papers/10.3390/nu14214673
The paper
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Triggiani, D., Donghia, R., Crudele, L., Rinaldi, R., Sabbà, C., Triggiani, V., De Pergola, G., & Piazzolla, G. (2022). Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study. Nutrients. https://doi.org/10.3390/nu14214673

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.